Flibanserin – (167933-07-5)

Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

It acts as a serotonin 5-HT1A receptor agonist and a 5-HT2A receptor antagonist. Flibanserin also binds to dopamine D4 receptors.

The drug increases sexual desire, the number of satisfying sexual events, and reduces distress associated with low sexual desire.

Flibanserin was initially developed as an antidepressant but was repurposed for HSDD after showing pro-sexual effects.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Flibanserin
https://www.medchemexpress.com/Flibanserin.html
https://www.medkoo.com/products/6829
https://www.mayoclinic.org/drugs-supplements/flibanserin-oral-route/description/drg-20152672